DocWire News Editors

DocwireNews

Patients in the intensive care unit (ICU) for COVID-19 had high rates of major arterial or venous thromboembolism (VTE), major adverse cardiovascular events, and symptomatic VTE, according to data from the CORONA-VTE study presented at the American Heart Association Scientific Sessions 2020.&ldquo;Systemic inflammation, endothelial injury, immobility, and hypercoagulability are thought to promote thromboembolic complications especially in the critical care setting,&rdquo; explained study presenter Gregory Piazza, MD, MS, director of the vascular medicine section at Brigham and Women&rsquo;s Hospital. &ldquo;Quantifying the risk of cardiovascular complications in the heterogeneous population of patients with COVID-19 has been hampered by limited sample size, restriction of focus to the ICU setting, variable outcome definitions, and differing thromboprophylaxis patterns.&rdquo;To learn more, Dr. Piazza and colleagues analyzed 1,114 patients diagnosed with COVID-19 in their healthcare network. Patients were analyzed by site of care: ICU (n=170), hospitalized non-ICU (n=229), and outpatient setting (n=715). The cohort was 22.3% Hispanic/Latinx and 44.2% non-white. The primary study outcome was a composite of adjudicated major arterial or venous thromboembolism at 30 days.It was common for patients to have cardiovascular risk factors including hypertension (35.8%), hyperlipidemia (28.6%) and diabetes (18.0%). The median length of stay for the ICU cohort was 16 days and was 5 days for the admitted non-ICU cohort. Thirty percent of ICU patients were still hospitalized by 30 days. The majority (89.4%) of patients in the ICU cohort and the non-ICU hospitalized cohort (84.7%) were prescribed prophylactic anticoagulation.&ldquo;Major arterial or venous thromboembolism, major adverse cardiovascular events, and symptomatic VTE occurred with high frequency over 30 days in ICU patients with COVID-19 despite nearly 90% thromboprophylaxis,&rdquo; Dr. Piazza said.The incidence of major arterial or VTE (35.3%), major cardiovascular adverse events (45.9%) and symptomatic venous thromboembolism (27.0%) were highest in the ICU cohort, followed by the hospitalized non-ICU cohort (2.6%, 6.1%, 2.2%, respectively).&ldquo;Interestingly our outpatients did not have any observed major adverse events,&rdquo; Dr. Piazza said.The researchers analyzed time from COVID-19 PCR diagnosis to major arterial and VTE. The risk for major thromboembolic events and symptomatic VTE seemed to really increase for the ICU cohort at around 5 days, Dr. Piazza noted. For major cardiovascular events, the risk appeared to increase earlier in the ICU stay.Multivariable analyses showed that in the ICU cohort there was a nearly sevenfold increase in the odds of major arterial or VTE events associated with adult respiratory distress syndrome (ARDS; adjusted odds ratio [OR]=6.69; 95% CI, 1.85 to 24.14). There was also almost a sixfold increase in the odds of major cardiovascular events associated with ARDS (adjusted OR=5.79; 95% CI, 2.01 to 16.69) and a twofold increase related to male gender (adjusted OR=2.07; 95% CI, 1.02 to 3.64). There was a &ldquo;staggering&rdquo; 24-fold increased risk for symptomatic VTE associated with ARDS (adjusted OR=24.39; 95% CI, 1.50 to 398.00).Dr. Piazza noted that catheter- and device-related deep vein thrombosis comprised a large proportion of VTE in the ICU cohort and may have inflated the study&rsquo;s estimate. Additionally, although 30-day follow-up data were available for 96% of patients, the researchers were unable to obtain follow-up data for 40 outpatients and, therefore, they were likely to have underestimated 30-day outcomes in this cohort.

Dr. Sadie Dobrozsi, Evolent

Rob Dillard

Genomics Tailors Breast Cancer Care, Cuts Unneeded Chemo

Genetics & Breast Cancer

Andrew Moreno

Extending Anticoagulation is Reasonable in Children with VTE, Data Suggest

Katie Kosko

DESTINY-Breast06: T-DXd Beats Chemo in HER2-Low HR+ mBC

Breast Cancer News

Latest News

Rates of Thromboembolic Complications High in COVID-19+ ICU Patients

AHA Scientific Sessions 2020

Patients in the intensive care unit (ICU) for COVID-19 had high rates of major arterial or venous thromboembolism (VTE), major adverse cardiovascular events, and symptomatic ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe